Kodiak Sciences Inc.
KODHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Kodiak Sciences Inc. (KOD) is listed under Biotechnology. The company carries a $5.51B market cap, placing it firmly in the mid-cap category. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD.
Market Cap
$5.51B
Beta
2.04
P/E (TTM)
—
P/E (Fwd)
-25.51
EPS (TTM)
$-4.19
EPS (Fwd)
$-3.44
ROE
-368.4%
ROA
-60.5%
Cash
$125.9M
Total Debt
$52.8M
Free CF
-$58.4M
52W Change
368.9%
Annual Financials
Cash vs Debt
Where KOD stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, KOD finished 108.90% above its 150-day moving average ($43.73) and 133.33% above its 200-day moving average ($39.15). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KOD overbought or oversold?
At the October 20, 2026 close, KOD's RSI(14) was 50.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $125.9M in cash comfortably exceeding the $52.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$58.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -368.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 2.04 means KOD is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, KOD has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Kodiak Sciences Inc.'s trajectory.